Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression.

The effects of dietary improvement on symptoms of depression and anxiety

(2019) Joseph Firth et al.   PSYCHOSOMATIC MEDICINE

Effort-based decision-making is affected by overweight/obesity in major depressive disorder

(2019) Rodrigo B. Mansur et al.   JOURNAL OF AFFECTIVE DISORDERS

Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response

(2019) Nadine Dreimüller et al.   JOURNAL OF AFFECTIVE DISORDERS

Depressive Symptom Clusters in Relation to Body Weight Status: Results From Two Large European Multicenter Studies

(2019) Sabrina Baldofski et al.   Frontiers in Psychiatry

P.032 A phase-2, double-blind, placebo-controlled, sequential parallel comparison design study of efficacy and safety of adjunctive pimavanserin in major depressive disorder

(2019) M. Fava et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study

(2018) Mary Hobart et al.   CURRENT MEDICAL RESEARCH AND OPINION

Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial

(2018) Manish K. Jha et al.   JOURNAL OF AFFECTIVE DISORDERS

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

(2018) Andrea Cipriani et al.   LANCET

Depression and obesity: evidence of shared biological mechanisms

(2018) Yuri Milaneschi et al.   MOLECULAR PSYCHIATRY

Efficacy of adjunctive low-dose cariprazine in major depressive disorder

(2018) Maurizio Fava et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Spencer L James et al.   LANCET

Mood Disorders and Gluten: It’s Not All in Your Mind! A Systematic Review with Meta-Analysis

(2018) Eleanor Busby et al.   Nutrients

The interface of depression and obesity

(2017) Nattinee Jantaratnotai et al.   Obesity Research & Clinical Practice

Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial

(2017) Takeshi Inoue et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

(2017) Akira Nishimura et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial

(2016) Maurizio Fava et al.   AMERICAN JOURNAL OF PSYCHIATRY

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

(2016) Raymond W. Lam et al.   CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review

(2016) Young Woo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies

(2016) Cynthia Richards et al.   JOURNAL OF AFFECTIVE DISORDERS

Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study

(2016) M. Amidfar et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants

(2016) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial

(2016) Elaheh Salardini et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression

(2016) Justine M. Kent et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

(2016) Robert M. Berman et al.   CNS SPECTRUMS

Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study

(2015) Ellen B. Dennehy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder

(2015) Leslie Citrome et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder

(2015) Paula L. Jacobsen et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder

(2015) Atul R. Mahableshwarkar et al.   JOURNAL OF CLINICAL PSYCHIATRY

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants

(2015) Michael E. Thase et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder

(2015) Michael E. Thase et al.   JOURNAL OF CLINICAL PSYCHIATRY

Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders

(2015) Rodrigo B. Mansur et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD

(2015) Atul R. Mahableshwarkar et al.   PSYCHOPHARMACOLOGY

Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder

(2014) Ching-Hua Lin et al.   JOURNAL OF AFFECTIVE DISORDERS

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

(2014) David Bakish et al.   JOURNAL OF PSYCHIATRY & NEUROSCIENCE

Inflammatory and Metabolic Dysregulation and the 2-Year Course of Depressive Disorders in Antidepressant Users

(2014) Nicole Vogelzangs et al.   NEUROPSYCHOPHARMACOLOGY

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

(2013) Michael R Liebowitz et al.   BMC Psychiatry

The utility of fat mass index vs. body mass index and percentage of body fat in the screening of metabolic syndrome

(2013) Pengju Liu et al.   BMC PUBLIC HEALTH

Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients

(2013) Chi-Un Pae et al.   CNS DRUGS

Efficacy and Safety of Desvenlafaxine 25 and 50▒Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients

(2013) NAKAO IWATA et al.   Journal of Psychiatric Practice

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

(2013) G Sanacora et al.   MOLECULAR PSYCHIATRY

The lack of association between components of metabolic syndrome and treatment resistance in depression

(2013) Marina Sagud et al.   PSYCHOPHARMACOLOGY

Relationship Between Obesity and Depression

(2013) Marisa S.P. Toups et al.   PSYCHOSOMATIC MEDICINE

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

(2012) Atul R. Mahableshwarkar et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

(2012) Rakesh Jain et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder

(2012) Neven Henigsberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study

(2011) Paula J. Gaynor et al.   CURRENT MEDICAL RESEARCH AND OPINION

Duloxetine in the treatment of binge eating disorder with depressive disorders: A placebo-controlled trial

(2011) Anna I. Guerdjikova et al.   INTERNATIONAL JOURNAL OF EATING DISORDERS

Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder

(2011) Siegfried Kasper et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Overweight, Obesity, and Depression

(2010) Floriana S. Luppino et al.   ARCHIVES OF GENERAL PSYCHIATRY

Changes in body weight during pharmacological treatment of depression

(2010) Rudolf Uher et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study☆

(2010) Brian Bortnick et al.   JOURNAL OF AFFECTIVE DISORDERS

Body weight as a predictor of antidepressant efficacy in the GENDEP project

(2009) Rudolf Uher et al.   JOURNAL OF AFFECTIVE DISORDERS

An Integrated Analysis of Olanzapine/Fluoxetine Combination in Clinical Trials of Treatment-Resistant Depression

(2009) Madhukar H. Trivedi et al.   JOURNAL OF CLINICAL PSYCHIATRY

Body Mass Index and Response to Antidepressants in Depressed Research Subjects

(2009) Nader Oskooilar et al.   JOURNAL OF CLINICAL PSYCHIATRY

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder

(2009) Ronald N. Marcus et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Association between obesity and depression in middle-aged women

(2008) Gregory E. Simon et al.   GENERAL HOSPITAL PSYCHIATRY